And just when are you going to change your definition of success to the expectation of success that stroke survivors have? 100% recovery. NOTHING LESS THAN THAT. Stop fucking around with your tyranny of low expectations of just survival.
Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke
A Meta-analysis
Yingfeng Lin, MD1; Volker Schulze, MD1; Maximilian Brockmeyer, MD1; et al
Claudio Parco, MD1; Athanasios Karathanos, MD1; Yvonne Heinen, MD1; Michael Gliem, MD2; Hans-Peter Hartung, MD2; Gerald Antoch, MD3; Sebastian Jander, MD2; Bernd Turowski, MD3; Stefan Perings, MD1; Malte Kelm, MD1,4; Georg Wolff, MD1
JAMA Neurol. Published online April 8, 2019. doi:10.1001/jamaneurol.2019.0525
Key PointsQuestion
Is there a benefit for short-term survival with endovascular thrombectomy vs medical therapy in acute ischemic stroke?
Findings In this meta-analysis of all randomized clinical trials of endovascular thrombectomy vs medical therapy cited in the 2018 American Stroke Association/American Heart Association guidelines for acute ischemic stroke, endovascular thrombectomy significantly reduced the risk for 90-day mortality compared with medical therapy, without a difference in risk of intracranial hemorrhage.
Meaning There is considerable evidence of the benefits of endovascular thrombectomy for survival during the first 90 days after acute ischemic stroke.
Importance
Although endovascular thrombectomy (EVT) in acute ischemic
stroke is recommended by guidelines to improve functional recovery, thus
far there are insufficient data on its association with mortality.
Objective To identify guideline-relevant trials of EVT vs medical therapy reporting 90-day mortality and perform a meta-analysis.
Data Sources All randomized clinical trials cited for recommendations on EVT vs medical therapy in the latest 2018 American Stroke Association/American Heart Association guidelines.
Study Selection Ten American Stroke Association/American Heart Association guideline–relevant randomized clinical trials of EVT vs medical therapy were selected for inclusion. Two EVT trials were excluded owing to infrequent use of EVT.
Data Extraction and Synthesis Data were abstracted by 2 independent investigators and double-checked by 4 others. Singular study data were integrated using the Cochran-Mantel-Haenszel method and a random-effects model to compute summary statistics of risk ratios (RR) with 95% CIs.
Main Outcomes and Measures Risk of 90-day mortality and 90-day intracranial hemorrhage was analyzed; sensitivity analyses were performed in early-window EVT trials (which included patients from the onset of symptoms onward) vs late-window EVT trials (which included patients from 6 hours after onset of symptoms onward).
Results In 10 trials with 2313 patients, EVT significantly reduced the risk for 90-day mortality by 3.7% compared with medical therapy (15.0% vs 18.7%; RR, 0.81; 95% CI, 0.68-0.98; P = .03). Trends were similar in early-window (RR, 0.83; 95% CI, 0.67-1.01; P = .06) and late-window trials only (RR, 0.76; 95% CI, 0.41-1.40; P = .38). There was no difference in the risk for intracranial hemorrhage in EVT vs medical therapy (4.2% vs 4.0%; RR, 1.11; 95% CI, 0.71-1.72; P = .65). Limitations of the studies include trial protocol heterogeneity and bias originating from prematurely terminated trials.
Conclusions and Relevance This meta-analysis of all evidence on EVT cited in the 2018 American Stroke Association/American Heart Association guidelines shows significant benefits for survival during the first 90 days after acute ischemic stroke compared with medical therapy alone.
Findings In this meta-analysis of all randomized clinical trials of endovascular thrombectomy vs medical therapy cited in the 2018 American Stroke Association/American Heart Association guidelines for acute ischemic stroke, endovascular thrombectomy significantly reduced the risk for 90-day mortality compared with medical therapy, without a difference in risk of intracranial hemorrhage.
Meaning There is considerable evidence of the benefits of endovascular thrombectomy for survival during the first 90 days after acute ischemic stroke.
Abstract
Objective To identify guideline-relevant trials of EVT vs medical therapy reporting 90-day mortality and perform a meta-analysis.
Data Sources All randomized clinical trials cited for recommendations on EVT vs medical therapy in the latest 2018 American Stroke Association/American Heart Association guidelines.
Study Selection Ten American Stroke Association/American Heart Association guideline–relevant randomized clinical trials of EVT vs medical therapy were selected for inclusion. Two EVT trials were excluded owing to infrequent use of EVT.
Data Extraction and Synthesis Data were abstracted by 2 independent investigators and double-checked by 4 others. Singular study data were integrated using the Cochran-Mantel-Haenszel method and a random-effects model to compute summary statistics of risk ratios (RR) with 95% CIs.
Main Outcomes and Measures Risk of 90-day mortality and 90-day intracranial hemorrhage was analyzed; sensitivity analyses were performed in early-window EVT trials (which included patients from the onset of symptoms onward) vs late-window EVT trials (which included patients from 6 hours after onset of symptoms onward).
Results In 10 trials with 2313 patients, EVT significantly reduced the risk for 90-day mortality by 3.7% compared with medical therapy (15.0% vs 18.7%; RR, 0.81; 95% CI, 0.68-0.98; P = .03). Trends were similar in early-window (RR, 0.83; 95% CI, 0.67-1.01; P = .06) and late-window trials only (RR, 0.76; 95% CI, 0.41-1.40; P = .38). There was no difference in the risk for intracranial hemorrhage in EVT vs medical therapy (4.2% vs 4.0%; RR, 1.11; 95% CI, 0.71-1.72; P = .65). Limitations of the studies include trial protocol heterogeneity and bias originating from prematurely terminated trials.
Conclusions and Relevance This meta-analysis of all evidence on EVT cited in the 2018 American Stroke Association/American Heart Association guidelines shows significant benefits for survival during the first 90 days after acute ischemic stroke compared with medical therapy alone.
Full Text
No comments:
Post a Comment